The Siteman Blood Cancer Center, acknowledged internationally as a pacesetter in revolutionary care, attracts sufferers from throughout the U.S. and abroad. The middle brings collectively the multidisciplinary experience of WashU Medication physicians who’ve a singular give attention to treating blood cancers, together with leukemia, lymphoma, a number of myeloma and myelodysplastic syndromes. They’ve lengthy been on the forefront of remodeling care and pushing the boundaries of what is attainable in managing these complicated cancers.
Such progress stems from a strong basis of research-informed care championed by leukemia professional John F. DiPersio, MD, PhD, the Virginia E. and Sam J. Golman Endowed Professor of Medication, who led WashU Medication’s Division of Oncology for greater than 25 years. He was instrumental in establishing Siteman’s bone marrow transplant program for sufferers with blood cancers as one of many world’s finest, and his ongoing analysis at WashU Medication continues to maneuver the sphere ahead. Along with growing novel cell-based immunotherapies, he’s centered on assuaging graft-versus-host illness, a probably lethal complication of bone marrow transplantation. His analysis has been basic to the FDA approval of medicines to mobilize stem cells for transplant and the primary drug accepted to deal with graft-versus-host illness.
WashU Medication’s experience in blood cancers runs deep. Doctor-scientist Daniel C. Link, MD, additionally focuses on leukemia and conducts revolutionary analysis aimed toward growing higher therapies for blood most cancers. He’s deputy director of Siteman and director of the Division of Oncology. Hyperlink is a world chief in understanding hematopoiesis, the method by which various kinds of blood cells are shaped and has helped develop WashU Medication’s hematopoietic malignancy analysis program into one of many prime such applications within the nation. He additionally leads efforts aimed toward boosting translational analysis and shifting promising investigational therapies – developed at WashU Medication – into scientific trials.
Along with Hyperlink, the Alan A. and Edith L. Wolff Distinguished Professor of Medication, the Siteman Blood Most cancers Heart is led by Amanda F. Cashen, MD, a professor of medication and affiliate chief of the Hematologic Malignancies Program, and Brad S. Kahl, MD, a professor of medication and director of the Lymphoma Program.
